Catheter Precision Inc. (VTAK) has divested its atherectomy catheter technology portfolio as part of a strategic realignment aimed at strengthening its core electrophysiology business. Under the transaction, the company will receive $15 million in upfront payments alongside a 5% equity stake in the acquiring entity, along with royalty streams extending across a ten-year period.
The divestiture represents a significant portfolio shift for the medical device manufacturer, allowing management to direct capital and operational resources toward its electrophysiology platform. The transaction structure, which includes both equity participation and deferred royalty payments, provides the company with ongoing financial exposure to the divested technology while freeing balance sheet capacity for strategic initiatives.
Market reaction to the announcement was muted, with VTAK shares declining 5.05% to close at $1.61 per share on the transaction news. The stock has been trading substantially below key technical levels, with current valuations proximate to its 52-week low range, reflecting broader market conditions for the company.